Literature DB >> 34194642

Risk Stratification Algorithm for Orthopedic Trauma Patients at Risk for Fat Embolism Syndrome.

Andrew Lowery1, Vineet Naran1, Robert Ames2, Akul Patel2, Frederick Ramsey3, Bridget Slattery2, Theresa Pazionis2.   

Abstract

BACKGROUND: Fat embolism syndrome (FES) is commonly reported in the setting of long bone and pelvic fractures, but the etiology and pathogenesis are unclear. The aim of this study was to identify clinical characteristics and laboratory findings that may place orthopedic trauma patients at a higher risk of developing FES.
METHODS: Electronic medical records were reviewed of all patients aged 18-89 years from 2015 to 2020 with a mention of FES in the patient chart who met Gurd and Wilson's criteria for diagnosis after experiencing orthopedic trauma. A 3:1 matched pair analysis was performed between FES patients and those with similar age, gender, and FES-associated fracture (femur, tibia, humerus, or pelvis fracture).
RESULTS: 18 patients with FES who met inclusion criteria were identified. Hypomagnesemia (OR = 7.43), hyperphosphatemia (OR = 6.24), hypoalbuminemia (OR = 3.78), blunt traumatic mechanism of injury (OR = 7.16) and a greater number of bones fractured (Avg/SD = 2.89/1.53) were seen more often in FES patients (all p-values < 0.05).
CONCLUSION: Findings of this study suggest that patients with hypomagnesemia, hyperphosphatemia, hypoalbuminemia, a blunt trauma mechanism of injury, and an increased number of bones fractured are at increased risk for the development of FES. This may be related to their roles in physiologic oncotic pressure and inflammatory response, and thus further investigation of these variables is necessary for the evaluation of FES prevention. LEVEL OF EVIDENCE: Level 3. © Indian Orthopaedics Association 2021.

Entities:  

Keywords:  Blunt trauma; FES; Fat embolism syndrome; Hyperphosphatemia; Hypoalbuminemia; Hypomagnesemia

Year:  2021        PMID: 34194642      PMCID: PMC8192641          DOI: 10.1007/s43465-021-00365-x

Source DB:  PubMed          Journal:  Indian J Orthop        ISSN: 0019-5413            Impact factor:   1.251


  14 in total

1.  The fat embolism syndrome.

Authors:  A R Gurd; R I Wilson
Journal:  J Bone Joint Surg Br       Date:  1974-08

2.  Free fatty acids, catecholamines, and arterial hypoxia in patients with fat embolism.

Authors:  P L Baker; J A Pazell; L F Peltier
Journal:  J Trauma       Date:  1971-12

Review 3.  Fat embolism syndrome: a review of the pathophysiology and physiological basis of treatment.

Authors:  H R Gossling; V D Pellegrini
Journal:  Clin Orthop Relat Res       Date:  1982-05       Impact factor: 4.176

4.  Fat embolism syndrome: history, definition, epidemiology.

Authors:  Max Talbot; Emil H Schemitsch
Journal:  Injury       Date:  2006-10       Impact factor: 2.586

5.  Phosphate regulation of vascular smooth muscle cell calcification.

Authors:  S Jono; M D McKee; C E Murry; A Shioi; Y Nishizawa; K Mori; H Morii; C M Giachelli
Journal:  Circ Res       Date:  2000-09-29       Impact factor: 17.367

Review 6.  Magnesium and the inflammatory response: potential physiopathological implications.

Authors:  Andrzej Mazur; Jeanette A M Maier; Edmond Rock; Elyett Gueux; Wojciech Nowacki; Yves Rayssiguier
Journal:  Arch Biochem Biophys       Date:  2006-04-19       Impact factor: 4.013

7.  Fat embolism syndrome.

Authors:  Paul D Stein; Abdo Y Yaekoub; Fadi Matta; Michael Kleerekoper
Journal:  Am J Med Sci       Date:  2008-12       Impact factor: 2.378

Review 8.  From the diagnosis to the therapeutic management: cerebral fat embolism, a clinical challenge.

Authors:  Maenia Scarpino; Giovanni Lanzo; Francesco Lolli; Antonello Grippo
Journal:  Int J Gen Med       Date:  2019-01-04

9.  Fat embolism syndrome.

Authors:  Michael E Kwiatt; Mark J Seamon
Journal:  Int J Crit Illn Inj Sci       Date:  2013-01

Review 10.  Hypoalbuminemia: Pathogenesis and Clinical Significance.

Authors:  Peter B Soeters; Robert R Wolfe; Alan Shenkin
Journal:  JPEN J Parenter Enteral Nutr       Date:  2018-10-04       Impact factor: 4.016

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.